Clinical Trial Update: PK Study of IV Formulation of GW856553 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of an intravenous formulation of GW856553 conducted by GlaxoSmithKline; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• GW856553

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cardiovascular Disease | Phase 1 | Status: COMPLETED